Impairment of circulating endothelial progenitors in Down syndrome
- Valerio Costa1,
- Linda Sommese2,
- Amelia Casamassimi3,
- Roberta Colicchio4,
- Claudia Angelini5,
- Valentina Marchesano6,
- Lara Milone7,
- Bartolomeo Farzati3,
- Alfonso Giovane7,
- Carmela Fiorito8,
- Monica Rienzo3,
- Marco Picardi9,
- Bice Avallone6,
- Massimiliano Marco Corsi10,
- Berardo Sarubbi11,
- Raffaele Calabrò11,
- Paola Salvatore12,
- Alfredo Ciccodicola†1Email author and
- Claudio Napoli†3
© Costa et al; licensee BioMed Central Ltd. 2010
Received: 17 February 2010
Accepted: 13 September 2010
Published: 13 September 2010
Pathological angiogenesis represents a critical issue in the progression of many diseases. Down syndrome is postulated to be a systemic anti-angiogenesis disease model, possibly due to increased expression of anti-angiogenic regulators on chromosome 21. The aim of our study was to elucidate some features of circulating endothelial progenitor cells in the context of this syndrome.
Circulating endothelial progenitors of Down syndrome affected individuals were isolated, in vitro cultured and analyzed by confocal and transmission electron microscopy. ELISA was performed to measure SDF-1α plasma levels in Down syndrome and euploid individuals. Moreover, qRT-PCR was used to quantify expression levels of CXCL12 gene and of its receptor in progenitor cells. The functional impairment of Down progenitors was evaluated through their susceptibility to hydroperoxide-induced oxidative stress with BODIPY assay and the major vulnerability to the infection with human pathogens. The differential expression of crucial genes in Down progenitor cells was evaluated by microarray analysis.
We detected a marked decrease of progenitors' number in young Down individuals compared to euploid, cell size increase and some major detrimental morphological changes. Moreover, Down syndrome patients also exhibited decreased SDF-1α plasma levels and their progenitors had a reduced expression of SDF-1α encoding gene and of its membrane receptor. We further demonstrated that their progenitor cells are more susceptible to hydroperoxide-induced oxidative stress and infection with Bartonella henselae. Further, we observed that most of the differentially expressed genes belong to angiogenesis, immune response and inflammation pathways, and that infected progenitors with trisomy 21 have a more pronounced perturbation of immune response genes than infected euploid cells.
Our data provide evidences for a reduced number and altered morphology of endothelial progenitor cells in Down syndrome, also showing the higher susceptibility to oxidative stress and to pathogen infection compared to euploid cells, thereby confirming the angiogenesis and immune response deficit observed in Down syndrome individuals.
Down syndrome (DS) is a complex disorder caused by trisomy of the entire or a critical portion of chromosome 21 (HSA21); it represents the most frequent genetic cause of mental retardation, with a frequency of about 1/1000 new-borns, and is associated with a huge number of congenital heart defects . DS individuals have also an increased risk of early-onset Alzheimer disease . Immunological and autoimmune disturbances, with high rates of infections and malignancies, are recurrent phenomena in DS pathogenesis , and infections still represent major cause of death in DS [3, 4]. Despite the increased risk of leukaemia, DS patients have a low incidence to develop solid tumors [5, 6], and a reduced incidence of diabetic retinopathy, suggesting, at least in part, a common angiogenesis' suppression [5, 7]. Impaired endothelial function at a young age, possibly due to increased oxidative stress and yet unknown mechanisms, is a common DS feature .
DS phenotype results from a dosage imbalance of HSA21 genes, although expression analyses have reported conflicting results [9, 10]. The over-expression of chromosome 21 genes greatly varies across the trisomic tissues [11, 12], and analyzing specific cell type/tissue, in easy-accessible and non-invasive manner, may be more productive [13, 14].
Growing interest is emerging on circulating endothelial progenitor cells (EPCs) and their pivotal role in the maintenance of endothelium integrity, repair after injury and postnatal neovascularization [15–17]. Many studies are providing encouraging insights into the use of EPCs in the clinical setting [18, 19]. Indeed, accumulating evidences indicate a reduced availability, and/or impaired EPC function, in cardiovascular and metabolic diseases [17, 20, 21]. EPCs number was recently shown to be impaired in DS fetuses and children [22, 23] and CD34+ haematopoietic progenitors exhibited a marked growth decrease in Ts65Dn - a DS mouse model - accounting, at least in part, for DS vascular anomalies and defective immune response to pathogens .
Bacterial toxins may trigger pathogenic events through the over-production of cytokines and chemokines, leading to the alteration of endothelial function and capillary leakage . Particularly, we recently demonstrated  that Bartonella henselae, a gram-negative intracellular bacteria responsible of vasoproliferative disorders in immunocompromised individuals [27, 28], adheres to and invades EPCs.
The present study was designed to pursue the molecular mechanisms contributing to immune, vascular and haematopoietic defective DS phenotypes, by investigating the number and functions of DS EPCs compared to euploid cells, also focusing on bioinformatics analysis of differentially expressed genes. Moreover, by using the previously described B. henselae model, we investigated the susceptibility of DS progenitors to this pathogen infection, also performing a detailed analysis of deregulated genes after Bartonella infection, with particular attention to angiogenesis and immune response pathways.
DS and euploid donors were recruited at the Institute of General Pathology, Section of Clinical Pathology, Faculty of Medicine, University of Milan, and at the Second University of Naples, and an approval statement was obtained by the ethics' review boards of both Institutions. Informed consent was obtained from all persons involved in all clinical investigation of this study according to the principles expressed in the Declaration of Helsinki.
All subjects recruited for EPC isolation were free of infection, and no individual was taking any medication known to affect immune system/response. DS and euploid individuals were 65% males and 35% females as gender and 28 ± 9 as mean age. The experiments, where not specified, were performed on at least six DS and age-matched euploid individuals.
Plasma samples were obtained from 50 DS individuals and 30 age matched euploids subdivided into three age subgroups (young 0-20 y.o.; adult 21-40 y.o.; old 41-60 y.o.) as described elsewhere .
EPCs were isolated from non-institutionalized individuals with DS and age-matched euploid donors.
EPCs were isolated as previously described . Briefly, PBMCs were isolated by density gradient centrifugation of peripheral blood samples on Histopaque-1077 (Sigma). Cells were washed twice with PBS and counted. PBMCs were plated on culture dishes pre-coated with gelatin and fibronectin and maintained in endothelial basal medium-2 (EBM2; Cell Systems). Cells were cultured at 37°C with 5% CO2 in a humidified atmosphere. After four days, non-adherent cells were removed and adherent cells were used for further analyses.
Bacterial strains and growth conditions
The B. henselae strain ATCC 49882 (LGC Promochem) was grown on Columbia agar supplemented with 5% defibrinated sheep blood (Oxoid) in a humidified atmosphere at 37°C and 5% CO2. For production of bacterial stock suspensions, bacteria were harvested after 7 days of culture until they reached the mid-exponential phase of growth (109 bacteria/ml), resuspended in Tryptone Soya Broth USP (Oxoid) containing 10% glycerol, and stored at -80°C. The number of viable bacteria in the frozen stocks was determined as previously described .
B. henselae infection
For infection, Bartonella stock solutions were thawed, washed and suspended in antibiotic-free cell culture medium, and sedimented onto cultured EPCs at different multiplicity of infection (MOI) of 50, 100, 250, 500 and 1000 . The MOI for infections was confirmed by plating serial dilutions of the infection inoculum. Assays were performed three times in triplicate.
Confocal immunofluorescence microscopy
EPCs were dual stained with Dil-Ac-LDL and lectin from Ulex europaeus and counted both by fluorescence microscopy and flow cytometry as previously described [26, 30]. Images were obtained by Zeiss LSM 510 with plan-apochromat X 63 (NA 1.4) oil immersion objective. EPCs images were used to measure cell size with ImageJ (http://rsb.info.nih.gov/ij/).
SDF-1α plasma levels
Commercially available SDF-1α ELISA kit (Quantikine, R&D Systems) was used to determine plasma SDF-1α levels. Tests were carried out at RT on freshly thawed plasma samples of 50 DS individuals and 30 age matched euploids subdivided into three age subgroups (young 0-20 y.o.; adult 21-40 y.o.; old 41-60 y.o.) . Concentration was determined by comparison with a standard curve, following manufacturer's instruction.
Transmission electron microscopy
After a short incubation with Trypsin/EDTA, DS and euploid EPCs, both infected and uninfected with B. henselae, were harvested, centrifuged and washed in PBS. After centrifugation at a speed of 400 g for 7 min, cells were fixed in 4% glutaraldehyde as described . Postfixation, dehydratation of specimen, semithin (2 μm) and ultrathin (80 nm) sections were performed as previously described . Semithin sections were analysed with a light microscope (Polivar Reichert-Jung). Ultrathin sections were examined with Leo 912 AB transmission electron microscope operating at 80 kV.
Oxidation-sensitive fluorescent probe, C11-BODIPY581/591 (C11-BO, Invitrogen), was loaded (2 μM final concentration) into the cells 30 min. before oxidative treatment. The samples were aliquoted in triplicate wells of a 24-well microplate, and fluorescence was determined with confocal laser microscopy at different times (0, 1, and 6 hours) from oxidant treatment. Between times, plates were maintained at 37°C in 5% CO2. To determine red fluorescence each microplate was excited at 543 nm (emission at 590 nm); for green fluorescence, microplates were excited at 488 nm (emission at 526 nm). Blank wells were also evaluated as well as C11-BO alone.
Microarray analysis and quantitative RT-PCR
Total RNA (10 μg) was isolated as previously described  [Additional file 1: Supplementary Methods]. A pool of three samples (a total 15 μg of cRNA) was used for each hybridization - 2 pools of three infected and three uninfected euploid and DS - on the Affymetrix U133 2.0 probe array cartridge as described elsewhere . Microarray data were submitted to Array Express (http://www.ebi.ac.uk/arrayexpress; provisional accession number E-MTAB-312). Results were validated by qRT-PCR and semi-qRT-PCR, performed as described , using primer pairs listed in [Additional file 2: Supplemental Table S1].
In silico significant pathway identification
Analysis of over-represented genes was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) [33, 34] and the PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification System [35 [Additional file 1: Supplementary Methods].
EPCs number, cell size differences, SDF-1α plasma levels, fluorescence intensity of C11-BO and qRT-PCRs data were reported as mean values, and results analysed by paired Student t test. P value < 0.05 was considered statistically significant [Additional file 1: Supplementary Methods].
EPC number and phenotype
SDF-1α plasma levels
EPC number is known to correlate to chemokines' plasma levels, such as SDF-1α (stromal derived factor-1α). Thus, we first measured by ELISA its plasma levels in peripheral blood of 30 euploid and 50 DS individuals, collected in three age subgroups . Then, comparing mean SDF-1α values we found a significant decrease of SDF-1α plasma levels in young and adults DS compared to age-matched euploid individuals (P = 0.02) (Figure 1D).
Moreover, we measured by quantitative RT-PCR the expression of SDF-1α encoding gene, CXCL12, and of its membrane receptor CXCR4. A significant decrease in the expression of CXCL12 (5-fold; P < 0.05) and CXCR4 (2-fold; P < 0.05) was observed in DS endothelial progenitors compared to euploid cells (Figure 1E).
B. henselaeinfection of endothelial progenitors
Oxidative stress in DS progenitors
To evaluate the protective effects of B. henselae, known to induce - albeit at low MOI (50) - long-term endothelial cell survival and proliferation [37, 38], the same experiment was performed on DS and euploid progenitors infected with a low MOI (about 50) of Bartonella. No differences in LP were observed in both DS and euploid infected cells compared to uninfected, in the absence of hydroperoxide treatment (data not shown). More interestingly, a significant decrease in LP was observed in Bartonella-infected DS progenitors vs uninfected (p < 0.01) (Figure 3A lower panel). This finding is in accordance to the previously reported beneficial effect of infection at low MOI of B. henselae [37, 38].
Moreover, it is known that a constitutive increase in S100B, due to HSA21 trisomy, is likely to induce ROS generation, leading to increased oxidative stress in DS , and the over-expression of SOD1 gene has been suggested to be responsible of oxidative damage to neurons . Thus, we measured the expression levels of both S100B and SOD1 genes in DS and euploid isolated EPCs, showing their significant over-expression in DS derived cells (Figure 3B).
Chromosome 21 expression profile
We chose a user fold-change of 2 and a P-value cut-off of 0.005 for selecting a list of differentially expressed genes, and we first focused on the HSA21 genes according to GenBank annotation. Thus, to evaluate the impact of an extra copy of chromosome 21 on DS progenitors we performed a detailed analysis of HSA21 genes in DS vs eupolid EPCs. We observed that only 109 out of a total of 386 genes annotated on HSA21 (NCBI RefSeq 36.3), were detected in this microarray analysis. Furthermore, 52 (about 14% of total HSA21 annotated genes) showed an evidence of differential expression in DS EPCs compared to euploid cells. In particular, 37 genes were up- and 15 down-regulated (72% up- and 28% down-regulated, respectively) [Additional file 4: Supplemental Table S2].
Although we observed relatively small up-regulation of chromosome 21 genes, significant changes in gene expression were not limited to HSA21 genes. Indeed, we observed a global and pronounced deregulation overall the chromosomes, possibly explained by dosage imbalance of HSA21 genes encoding transcriptional factors or gene expression modulators (Figure 4A; Additional file 4: Supplemental Table S2).
A less frequently explored gene characteristic for microarray analysis is the chromosomal location of the genes, especially when studying diseases caused by genome alterations. First we demonstrated, by using chi-squared association tests, that differentially expressed genes are not uniformly distributed along the chromosomes. We observed that in DS EPCs the chromosomes 21 - as expected - and 19 were enriched for differentially expressed genes compared to the other chromosomes (α 0.001; P = 6.7E-0.6; Additional file 5: Supplemental Figure S2). As a proof of the robustness of our findings, the analysis was repeated with different fold-change and P cut-offs, reporting similar qualitative findings. Moreover, by using positional gene enrichment (PGE) approach  to map a set of genes to the exact location on chromosome [Additional file 6: Supplemental Figure S3], we observed that chromosome 19 has the highest percent of deregulated genes [Additional file 3: Supplemental Figure S1A] and, in particular, that the enriched p12 band contains most of the genes encoding for transcription factors of the zinc finger protein superfamily.
Gene pathways' perturbation in DS progenitors
By using the same selection parameters, the comparison of global DS and euploid expression profiles revealed that, after filtering ("Materials and Methods"), 2913 genes (2489 of them with single probe and 424 with multiple probes) were differentially expressed, on a total of 11327 distinct genes considered. By using DAVID and PANTHER Classification System, differentially expressed genes were categorized according to their known or hypothetical biological function, and the enrichment for specific gene pathways was evaluated. The analysis revealed that most of the deregulated genes were involved in "angiogenesis", "inflammation mediated by cytokines and chemokines", "integrins" and "interleukines" signaling pathways (Figure 4B). A particular enrichment was also observed for cell cycle and cell cycle-related genes (Figure 4C).
Differential expression of angiogenesis-related genes in DS vs C endothelial progenitors
Chemokine (C-X-C motif) ligand 10
Interferon stimulated gene 20
SAM domain- and HD domain-containing protein 1
Interferon-γ stimulated; angiogenesis inhibitor
Adhesion and homing of EPC
Chemokine (C-X-C motif) ligand 12
10.2 D; 5.7 D
Mobilization and recruitment of EPCs
Chemokine (C-X-C motif) receptor 4
Endothelial cells migration and homing
Chemokine (C-X-C motif) receptor 7
Endothelial cells migration and homing
13.6 D; 3.5 D
Promotes migration and proliferation of endothelial cells
Endothelin receptor type B
Migration, proliferation of endothelial cells
Vascular endothelial growth factor A
VEGF-mediated angiogenic response
Since evidences indicate that chemokines, cytokines and soluble factors affect the mobilization and recruitment of endothelial progenitors [42, 43], we evaluated the expression of some crucial genes by quantitative RT-PCR (Figure 1E and 4D). Particularly, we observed a down-regulation of CXCR4 receptor and of its ligand, encoded by CXCL12 gene, in DS progenitors compared to euploid cells (Figure 1E), the over-expression of RCAN1 gene (or DSCR1) and the down-regulation of CXCR7 receptor (Figure 4D), which play a key role in endothelial cells migration and homing. No significant differential expression was observed for IL8 and DYRK1A genes in DS progenitors compared to euploid (Figure 4D).
B. henseale-induced gene expression variations
A similar approach for gene list selection was used to investigate the genetic response of DS-EPCs to B. henselae infection at a 100 MOI.
GO term enrichment analysis  showed that a considerable number of induced/repressed genes belong to immune and inflammatory response pathways [Additional file 7: Supplemental Figure S4], with the majority of genes annotated within the "Jak/STAT" and "Cytokine-cytokine receptor interaction" pathways. Furthermore, we categorized the most prominently up-regulated genes in DS infected EPCs in two related functional classes: "Interferons related/induced genes" and "cytokines and chemokines", consisting of 19 and 32 genes, respectively. The same approach was then used for infected euploid cells. Transcriptional levels of related genes, observed by microarray, are shown in [Additional file 8: Supplemental Table S3].
Other deregulated genes - involved in cell cycle regulation and gene expression - were further identified, many of which are known to be targets of interferon action as a consequence of the anti-proliferative effects.
Alteration of EPC number has been described in a wide range of conditions, such as cardiovascular, inflammatory, immune, and infectious diseases [21, 44]. A decreased in vitro growth capacity of bone marrow-derived progenitors in DS mouse model Ts65Dn  and a reduced number of CD34+ in DS fetuses and children were also reported . More recently, Diller et al. (2008) reported an impairment of CD34+/AC133+/KDR+ cells in a small subset of DS individuals affected by Eisenmenger syndrome . Despite the use of different experimental approaches and the limited number of individuals, the reduced number of circulating progenitors is an important common finding. These evidences may possibly account for the differences in angiogenesis, inflammatory and immune response reported in DS .
Here, we have shown that DS patients exhibit a marked reduction of ≈ 40% in the number of EPCs, also displaying a significant increase in cell size and major detrimental morphological changes (i.e., cell vacuolization and high number of active lysosomes). The reduced number of progenitors could be associated with alterations in the cell cycle; however, we did not find any significant difference between the groups [Additional file 3: Supplemental Figure S1C]. Thus, we investigated other possible mechanisms responsible for the observed EPCs impairment, such as mobilization/homing and oxidative stress susceptibility.
Growing evidences indicate that chemokines and cytokines, such as SDF-1α and its receptor CXCR4, play a crucial role in the mobilization and homing of EPCs from bone marrow [45, 46], also affecting cell proliferation [41, 42]. Our findings of a significant decrease in SDF-1α plasma levels in young DS - compared to age-matched euploids - and a strong decrease of CXCL12 and CXCR4 gene transcription in their EPCs, suggest a link with the reduced number of circulating progenitors and the angiogenesis suppression observed in DS.
These results are strengthened by microarray analysis, indicating that DS progenitors have a pronounced perturbation, at least at transcriptional level, in the angiogenesis and cell cycle pathways. Indeed, by using this approach we demonstrated the transcriptional deregulation of CXCR7, IL8 and RCAN1 genes, crucial factors involved in endothelial cells' migration, homing and angiogenesis [47–49]. Moreover, we found a down-regulation of CASP8, which has been demonstrated to have a novel apoptosis-unrelated role in proangiogenic cells , although this gene was found to be associated with breast cancer by gene-based association study, and its down-regulation has also been reported in breast cancer .
We recently demonstrated the relevance of oxidative stress on the number and function of progenitor cells . Besides, it is known that oxidative stress is a crucial issue in the pathogenesis of DS, especially due to the high incidence of Alzheimer-like disease at young age . It has been also suggested that constitutive expression of trisomic genes, S100B and SOD1, is likely to represent a leading cause of ROS generation and increased oxidation in DS neurons [39, 40]. Oxidative stress relevance in DS fetuses was also highlighted by microarray analysis of uncultured amniotic fluid .
Here, we have assessed, by both experimental evidences and microarray analysis, that DS progenitors are more susceptible to hydroperoxide-induced LP and significantly over-express S100B and SOD1 genes. These findings strengthen the hypothesis of their involvement in the susceptibility to oxidation observed in DS endothelial progenitors.
In our study we have infected DS progenitors with a human pathogen, B. henselae, responsible of vasoproliferative diseases such as bacillary angiomatosis and peliosis in immunocompromised patients [27, 28], previously demonstrated to adhere to and invade EPCs . Particularly, we investigated the effect of infection on DS progenitors' number, morphology and oxidative stress response. After hydroperoxide treatment, we observed a significant LP decrease in Bartonella-infected DS progenitors compared to uninfected DS cells. This finding confirms the beneficial effect of B. henselae infection at low MOI on mature endothelial cells' survival [37, 38].
In contrast, a reduced cell number in both DS and euploid groups was observed after Bartonella infection at higher MOIs; however, detrimental changes were visible only in DS EPCs, displaying a higher number of invasomes and infected cells compared to euploid cells.
The molecular basis of such Bartonella-induced detrimental effect on endothelial progenitors of DS was investigated at a transcriptional level by microarray. Significant up-regulation of the Jak/STAT pathway was observed only within infected DS progenitors, whereas, on the opposite, infected euploid cells displayed a significant down-regulation. These findings strengthen the hypothesis that transcriptional analysis of EPCs is clearly of major interest in the context of this syndrome. Indeed, the activation of ISGs, involved in the immune response against infections and in tumor surveillance , also inhibits angiogenesis by decreasing the production of angiogenic factors such as VEGF and IL8 . Our results clearly show that a similar ISGs activation occurs in infected DS progenitor cells, and, albeit at lower levels, in uninfected DS progenitors (data not shown).
Pathologic immune and inflammatory responses are regulated by the cross-talk between interferons and TNFα , as well as deregulation of chemokines/cytokines greatly affects the mobilization and recruitment of endothelial progenitors. The imbalance between ISGs and other molecules might be of great immunological relevance concerning the well-known DS haematological defects.
Physiological angiogenesis plays a central role in the embryogenesis and placental development; on the other hand, pathological angiogenesis represents a critical issue in the progression of many diseases, such as solid tumor growth and retinopathy.
Individuals with Down syndrome, due to decreased incidence of angiogenesis-dependent diseases, have been postulated to be a systemic anti-angiogenesis model. Indeed, they exhibit a significantly increased anti-angiogenic surveillance, possibly due to increased expression of anti-angiogenic regulators on chromosome 21 .
However, it has been shown a complex regulation of gene expression not only related to gene copy number, with several genes escaping the rule of "increased transcription proportional to the gene copy number" [58, 59]. This findings suggest that many pathological traits observed in DS may be controlled by other more complex and, above all tissue-specific, regulatory mechanisms .
Our study shows that circulating endothelial progenitors are reduced in patients with DS, possibly correlating to the low SDF-1α plasma levels, to a reduced expression of its membrane receptor in these cells, and to their higher oxidative stress and pathogen infection susceptibility compared to euploid cells. A significant perturbation in the angiogenesis and inflammation gene pathways was also observed by microarray analysis, highlighting that gene expression analysis is a crucial issue for the study of common diseases. Endothelial dysfunction, angiogenesis' suppression and infection recurrence are hallmarks of DS, and the impairment in the number and function of circulating progenitors may account for some of their pathological features. Further studies are needed to understand possible therapeutic implications of circulating EPCs in Down syndrome.
We thank the patients and individuals recruited as controls for their participation. This work was supported by Legge 5, Regione Campania 2008 to Prof. A. Ciccodicola; PRIN 2006, Foundation Jerome Lejeune, and Regione Campania 2008 to Prof. C. Napoli; and Progetto di Rilevante Interesse Nazionale Ministero Italiano Università e Ricerca 2006 [grant number 2006068944_001] "Basi genetiche e molecolari della patogenicità batterica" to Prof. P. Salvatore.
- Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM: Down syndrome--recent progress and future prospects. Hum Mol Genet. 2009, 18: 75-83. 10.1093/hmg/ddp010.View Article
- Gillespie KM, Dix RJ, Williams AJ, Newton R, Robinson ZF, Bingley PJ, Gale EA, Shield JP: Islet autoimmunity in children with Down's syndrome. Diabetes. 2006, 55: 3185-3188. 10.2337/db06-0856.View ArticlePubMed
- Ugazio AG, Maccario R, Notarangelo LD, Burgio GR: Immunology of Down syndrome: a review. Am J Med Genet Suppl. 1990, 7: 204-212.PubMed
- Garrison MM, Jeffries H, Christakis DA: Risk of death for children with down syndrome and sepsis. J Pediatr. 2005, 147: 748-752. 10.1016/j.jpeds.2005.06.032.View ArticlePubMed
- Folkman J: Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov. 2007, 6: 273-286. 10.1038/nrd2115.View ArticlePubMed
- Hasle H, Clemmensen IH, Mikkelsen M: Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet. 2000, 355: 165-169. 10.1016/S0140-6736(99)05264-2.View ArticlePubMed
- Fulcher T, Griffin M, Crowley S, Firth R, Acheson R, O' Meara N: Diabetic retinopathy in Down's syndrome. Br J Ophthalmol. 1998, 82: 407-409. 10.1136/bjo.82.4.407.PubMed CentralView ArticlePubMed
- Cappelli-Bigazzi M, Santoro G, Battaglia C, Palladino MT, Carrozza M, Russo MG, Pacileo G, Calabrò R: Endothelial cell function in patients with Down's syndrome. Am J Cardiol. 2004, 94: 392-395. 10.1016/j.amjcard.2004.04.047.View ArticlePubMed
- FitzPatrick DR, Ramsay J, McGill NI, Shade M, Carothers AD, Hastie ND: Transcriptome analysis of human autosomal trisomy. Hum Mol Genet. 2002, 11: 3249-3256. 10.1093/hmg/11.26.3249.View ArticlePubMed
- Mao R, Zielke CL, Zielke HR, Pevsner J: Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics. 2003, 81: 457-467. 10.1016/S0888-7543(03)00035-1.View ArticlePubMed
- Li CM, Guo M, Salas M, Schupf N, Silverman W, Zigman WB, Husain S, Warburton D, Thaker H, Tycko B: Cell type-specific over-expression of chromosome 21 genes in fibroblasts and fetal hearts with trisomy 21. BMC Med Genet. 2006, 7: 24-10.1186/1471-2350-7-24.PubMed CentralView ArticlePubMed
- Sommer CA, Pavarino-Bertelli EC, Goloni-Bertollo EM, Henrique-Silva F: Identification of dysregulated genes in lymphocytes from children with Down syndrome. Genome. 2008, 51: 19-29. 10.1139/G07-100.View ArticlePubMed
- Gardiner K: Gene-dosage effects in Down syndrome and trisomic mouse models. Genome Biol. 2004, 5: 244-10.1186/gb-2004-5-10-244.PubMed CentralView ArticlePubMed
- Antonarakis SE, Epstein CJ: The challenge of Down syndrome. Trends Mol Med. 2006, 12: 473-479. 10.1016/j.molmed.2006.08.005.View ArticlePubMed
- Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA: Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007, 109: 1801-1809. 10.1182/blood-2006-08-043471.PubMed CentralView ArticlePubMed
- Hirschi KK, Ingram DA, Yoder MC: Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008, 28: 1584-1595. 10.1161/ATVBAHA.107.155960.View ArticlePubMed
- Zampetaki A, Kirton JP, Xu Q: Vascular Repair by Endothelial Progenitor Cells. Cardiovascular Research. 2008, 78: 413-421. 10.1093/cvr/cvn081.View ArticlePubMed
- Krenning G, van Luyn MJ, Harmsen MC: Endothelial progenitor cell-based neovascularization: implications for therapy. Trends Mol Med. 2009, 15: 180-189. 10.1016/j.molmed.2009.02.001.View ArticlePubMed
- Shantsila E, Watson T, Lip GY: Endothelial progenitor cells in cardiovascular disorders. Journal of the American College of Cardiology. 2007, 49: 741-752. 10.1016/j.jacc.2006.09.050.View ArticlePubMed
- Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S: Number and migratory activity of circulating andothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circulation Research. 2001, 89: e1-7. 10.1161/hh1301.093953.View ArticlePubMed
- Sabatier F, Camoin-Jau L, Anfosso F, Sampol J, Dignat-George F: Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. J Cell Mol Med. 2009, 13: 454-471. 10.1111/j.1582-4934.2008.00639.x.PubMed CentralView ArticlePubMed
- Holmes DK, Bates N, Murray M, Ladusans EJ, Morabito A, Bolton-Maggs PH, Johnston TA, Walkenshaw S, Wynn RF, Bellantuono I: Hematopoietic progenitor cell deficiency in fetuses and children affected by Down's syndrome. Exp Hematol. 2006, 34: 1611-1615. 10.1016/j.exphem.2006.10.013.View ArticlePubMed
- Diller GP, van Eijl S, Okonko DO, Howard LS, Ali O, Thum T, Wort SJ, Bédard E, Gibbs JS, Bauersachs J, Hobbs AJ, Wilkins MR, Gatzoulis MA, Wharton J: Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation. 2008, 117: 3020-3030. 10.1161/CIRCULATIONAHA.108.769646.View ArticlePubMed
- Jablonska B, Ford D, Trisler D, Pessac B: The growth capacity of bone marrow CD34 positive cells in culture is drastically reduced in a murine model of Down syndrome. C R Biol. 2006, 329: 726-732. 10.1016/j.crvi.2006.06.004.View ArticlePubMed
- Mantovani A, Sozzani S, Introna M: Endothelial activation by cytokines. Ann N Y Acad Sci. 1997, 832: 93-116. 10.1111/j.1749-6632.1997.tb46240.x.View ArticlePubMed
- Salvatore P, Casamassimi A, Sommese L, Fiorito C, Ciccodicola A, Rossiello R, Avallone B, Grimaldi V, Costa V, Rienzo M, Colicchio R, Williams-Ignarro S, Pagliarulo C, Prudente ME, Abbondanza C, Lamberti F, Baroni A, Buommino E, Farzati B, Tufano MA, Ignarro LJ, Napoli C: Detrimental effects of Bartonella henselae are counteracted by L-arginine and nitric oxide in human endothelial progenitor cells. Proc Natl Acad Sci USA. 2008, 105: 9427-9432. 10.1073/pnas.0803602105.PubMed CentralView ArticlePubMed
- Dehio C: Bartonella-host-cell interactions and vascular tumour formation. Nat Rev Microbiol. 2005, 3: 621-631. 10.1038/nrmicro1209.View ArticlePubMed
- Kunz S, Oberle K, Sander A, Bogdan C, Schleicher U: Lymphadenopathy in a novel mouse model of Bartonella-induced cat scratch disease results from lymphocyte immigration and proliferation and is regulated by interferon-alpha/beta. Am J Pathol. 2008, 172: 1005-1018. 10.2353/ajpath.2008.070591.PubMed CentralView ArticlePubMed
- Dogliotti G, Galliera E, Licastro F, Corsi MM: Age-related changes in plasma levels of BDNF in Down syndrome patients. Immun Ageing. 2010, 7: 2-10.1186/1742-4933-7-2.PubMed CentralView ArticlePubMed
- Casamassimi A, Balestrieri ML, Fiorito C, Schiano C, Maione C, Rossiello R, Grimaldi V, Del Giudice V, Balestrieri C, Farzati B, Sica V, Napoli C: Comparison between total endothelial progenitor cell isolation versus enriched CD133+ culture. J Biochem. 2007, 141: 503-511. 10.1093/jb/mvm060.View ArticlePubMed
- Avallone B, Porritiello M, Esposito D, Mutone R, Balsamo G, Marmo F: Evidence for hair cell regeneration in the crista ampullaris of the lizard Podarcis sicula. Hear Res. 2003, 178: 79-88. 10.1016/S0378-5955(03)00040-6.View ArticlePubMed
- Costa V, Conte I, Ziviello C, Casamassimi A, Alfano G, Banfi S, Ciccodicola A: Identification and expression analysis of novel Jakmip1 transcripts. Gene. 2007, 402: 1-8. 10.1016/j.gene.2007.07.001.View ArticlePubMed
- Hosack DA, Dennis G, Sherman BT, Lane HC, Lempicki RA: Identifying biological themes within lists of genes with EASE. Genome Biol. 2003, 4: R70-10.1186/gb-2003-4-10-r70.PubMed CentralView ArticlePubMed
- Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4: 44-57. 10.1038/nprot.2008.211.View ArticlePubMed
- Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A: PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003, 13: 2129-2141. 10.1101/gr.772403.PubMed CentralView ArticlePubMed
- Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, Dimmller S: Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. Blood. 2004, 104: 3591-3597. 10.1182/blood-2003-12-4103.View ArticlePubMed
- Kirby JE, Nekorchuk DM: Bartonella-associated endothelial proliferation depends on inhibition of apoptosis. Proc Natl Acad Sci USA. 2002, 99: 4656-4661. 10.1073/pnas.072292699.PubMed CentralView ArticlePubMed
- Pulliainen AT, Dehio C: Bartonella henselae: subversion of vascular endothelial cell functions by translocated bacterial effector proteins. Int J Biochem Cell Biol. 2009, 41: 507-510. 10.1016/j.biocel.2008.10.018.View ArticlePubMed
- Esposito G, Imitola J, Lu J, De Filippis D, Scuderi C, Ganesh VS, Folkerth R, Hecht J, Shin S, Iuvone T, Chesnut J, Steardo L, Sheen V: Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. Hum Mol Genet. 2008, 17: 440-457. 10.1093/hmg/ddm322.View ArticlePubMed
- Lee M, Hyun D, Jenner P, Halliwell B: Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis. J Neurochem. 2001, 76: 957-965. 10.1046/j.1471-4159.2001.00107.x.View ArticlePubMed
- De Preter K, Barriot R, Speleman F, Vandesompele J, Moreau Y: Positional gene enrichment analysis of gene sets for high-resolution identification of overrepresented chromosomal regions. Nucleic Acids Res. 2008, 36: e43-10.1093/nar/gkn114.PubMed CentralView ArticlePubMed
- Hristov M, Wolfgang W, Weber PC: Endothelial progenitor cells mobilization differentiation and homing. Arterioscler Thromb Vasc Biol. 2003, 23: 1185-1189. 10.1161/01.ATV.0000073832.49290.B5.View ArticlePubMed
- Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, Dotta F, Sorrentino V: Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia. 2008, 51: 1296-1305. 10.1007/s00125-008-0939-6.View ArticlePubMed
- Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005, 111: 2981-2987. 10.1161/CIRCULATIONAHA.104.504340.View ArticlePubMed
- Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM, Asahara T: Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 2003, 107: 1322-1328. 10.1161/01.CIR.0000055313.77510.22.View ArticlePubMed
- Walter DH, Haendeler J, Reinhold J, Rochwalsky U, Seeger F, Honold J, Hoffmann J, Urbich C, Lehmann R, Arenzana-Seisdesdos F, Aicher A, Heeschen C, Fichtlscherer S, Zeiher AM, Dimmeler S: Impaired CXCR4 signaling contributes to the reduced neovascularisation capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res. 2005, 97: 1142-1151. 10.1161/01.RES.0000193596.94936.2c.View ArticlePubMed
- Waugh DJ, Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 2008, 14: 6735-6741. 10.1158/1078-0432.CCR-07-4843.View ArticlePubMed
- Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006, 203: 2201-2213. 10.1084/jem.20052144.PubMed CentralView ArticlePubMed
- Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, Korenberg JR, Folkman J, Daley GQ, Aird WC, Galdzicki Z, Ryeom S: Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009, 459: 1126-1130. 10.1038/nature08062.PubMed CentralView ArticlePubMed
- Scharner D, Rössig L, Carmona G, Chavakis E, Urbich C, Fischer A, Kang TB, Wallach D, Chiang YJ, Deribe YL, Dikic I, Zeiher AM, Dimmeler S: Caspase-8 is involved in neovascularization-promoting progenitor cell functions. Arterioscler Thromb Vasc Biol. 2009, 29: 571-578. 10.1161/ATVBAHA.108.182006.View ArticlePubMed
- Wu Y, Alvarez M, Slamon DJ, Koeffler P, Vadgama JV: Caspase 8 and maspin are downregulated in breast cancer cells due to CpG site promoter methylation. BMC Cancer. 2010, 10: 32-10.1186/1471-2407-10-32.PubMed CentralView ArticlePubMed
- Fiorito C, Rienzo M, Crimi E, Rossiello R, Balestrieri ML, Casamassimi A, Muto F, Grimaldi V, Giovane A, Farzati B, Mancini FP, Napoli C: Antioxidants increase number of progenitor endothelial cells through multiple gene expression pathways. Free Radic Res. 2008, 42: 754-762. 10.1080/10715760802357057.View ArticlePubMed
- Zana M, Janka Z, Kálmán J: Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol Aging. 2007, 28: 648-676. 10.1016/j.neurobiolaging.2006.03.008.View ArticlePubMed
- Slonim DK, Koide K, Johnson KL, Tantravahi U, Cowan JM, Jarrah Z, Bianchi DW: Functional genomic analysis of amniotic fluid cell-free mRNA suggests that oxidative stress is significant in Down syndrome fetuses. Proc Natl Acad Sci USA. 2009, 106: 9425-9429. 10.1073/pnas.0903909106.PubMed CentralView ArticlePubMed
- Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR: Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007, 6: 975-990. 10.1038/nrd2422.View ArticlePubMed
- Rosewicz S, Detjen K, Scholz A, von Marschall Z: Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology. 2004, 80: 85-93. 10.1159/000080748.View ArticlePubMed
- Ryeom S, Folkman J: Role of Endogenous Angiogenesis Inhibitors in Down Syndrome. J Craniofac Surg. 2009, 20: 595-596. 10.1097/SCS.0b013e3181927f47.View ArticlePubMed
- Lyle R, Gehrig C, Neergaard-Henrichsen C, Deutsch S, Antonarakis SE: Gene expression from the aneuploid chromosome in a trisomy mouse model of down syndrome. Genome Res. 2004, 14: 1268-1274. 10.1101/gr.2090904.PubMed CentralView ArticlePubMed
- Kahlem P, Sultan M, Herwig R, Steinfath M, Balzereit D, Eppens B, Saran NG, Pletcher MT, South ST, Stetten G, Lehrach H, Reeves RH, Yaspo ML: Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res. 2004, 14: 1258-1267. 10.1101/gr.1951304.PubMed CentralView ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1755-8794/3/40/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.